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Abstract
T cell receptors (TCRs) are key to antigen-specific immunity and are increasingly being explored as therapeutics, most visibly
in cancer immunotherapy. As TCRs typically possess only low-to-moderate affinity for their peptide/MHC (pMHC) ligands,
there is a recognized need to develop affinity-enhanced TCR variants. Previous in vitro engineering efforts have yielded
remarkable improvements in TCR affinity, yet concerns exist about the maintenance of peptide specificity and the biological
impacts of ultra-high affinity. As opposed to in vitro engineering, computational design can directly address these issues, in
theory permitting the rational control of peptide specificity together with relatively controlled increments in affinity. Here
we explored the efficacy of computational design with the clinically relevant TCR DMF5, which recognizes nonameric and
decameric epitopes from the melanoma-associated Melan-A/MART-1 protein presented by the class I MHC HLA-A2. We
tested multiple mutations selected by flexible and rigid modeling protocols, assessed impacts on affinity and specificity, and
utilized the data to examine and improve algorithmic performance. We identified multiple mutations that improved binding
affinity, and characterized the structure, affinity, and binding kinetics of a previously reported double mutant that exhibits
an impressive 400-fold affinity improvement for the decameric pMHC ligand without detectable binding to non-cognate
ligands. The structure of this high affinity mutant indicated very little conformational consequences and emphasized the
high fidelity of our modeling procedure. Overall, our work showcases the capability of computational design to generate
TCRs with improved pMHC affinities while explicitly accounting for peptide specificity, as well as its potential for generating
TCRs with customized antigen targeting capabilities.
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Introduction
T cell receptors (TCRs) are key elements of adaptive immunity,
as they specifically recognize antigenic peptides bound to MHC
proteins (pMHCs) on cell surfaces and are responsible for initiating
immune responses against targeted cells. The TCR-pMHC
interaction is of considerable importance in health and disease,
notably in transplantation, autoimmunity, and is a target for
development of vaccines and therapeutics for infectious disease
and cancer [1–3]. For example, the adoptive transfer of genetically
engineered T cells, whereby tumor-specific TCRs are transduced
into T cells and then infused into the patient, is being explored as a
means for cancer immunotherapy. Clinical trials of such
genetically engineered T cells have shown promise in the
treatment metastatic melanoma [4–6] and synovial cell carcinoma
[7], leading to durable tumor regression and long-term survival in
patients.
The observations that TCRs have relatively weak affinities
towards pMHC (typically 1–300 mM; ,1000-fold lower than
mature antibody/antigen interactions) and that pMHC affinities
are correlated to some extent with in vivo potency [8] have led to a
number of efforts to engineer TCRs with enhanced binding
affinity. These efforts include in vitro selection [9–13] as well as
computational structure-based design [14–16], resulting in up to
1,000,000-fold improvements in affinity. However, a major
concern in enhancing TCR affinity is maintenance of peptide
specificity. As TCRs recognize peptides presented by MHC
proteins, yet invariably form contacts to both peptide and MHC
[17], enhancements to TCR affinity risk dangerous cross-reactivity
if affinity-enhancing substitutions preferentially target the MHC
protein. Such ‘‘off-target’’ interactions can be challenging to
predict from peptide sequence and are a major concern for high
affinity TCRs [18]. Indeed, the unanticipated cross-reactivity of a
high affinity TCR resulted in serious consequences and deaths in a
recent clinical trial [19]. Additionally, significant enhancements in
antigen-specific affinity may be detrimental for T cell activity, as
there is evidence of a TCR ‘‘threshold affinity’’ above which T cell
responsiveness is attenuated [20,21]. Thus, careful control of
affinity and specificity is crucial in the development of enhanced
TCRs for therapeutic purposes.
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The ab TCR DMF5 was originally isolated from tumor
infiltrating lymphocytes present in a patient with metastatic
melanoma [22]. DMF5 recognizes the 27–35 nonameric and
26–35 decameric peptide epitopes from the MART-1 melanoma
antigen presented by the class I MHC protein HLA-A*0201
(HLA-A2), and was the second TCR to be used in clinical trials of
genetically engineered T cells [5]. Without knowledge of structure
or affinity, Robbins and colleagues previously examined a series of
point mutations in DMF5, generating variants that resulted in
improved antigen-specific responses yet also showed evidence of
reduced specificity, underscoring the need for incorporating
structural information in the design process [23]. More recently,
the DMF5 TCR has been crystallized by our laboratory in
complex with both the MART-1 nonameric epitope (AAGI-
GILTV; referred to as AAG) as well as the anchor-modified
decameric epitope (ELAGIGILTV; referred to as ELA), both
bound to HLA-A2 [24]. The structures show that despite the
significant difference in peptide conformation between the ELA/
HLA-A2 and AAG/HLA-A2 ligands [24], DMF5 engages them
with an identical binding mode. These structures along with
associated affinity measurements provide an ideal opportunity to
explore the applicability of computational structure-based design
for rationally enhancing a clinically relevant TCR, while
simultaneously exploring the impact on peptide specificity.
Utilizing a refined algorithm initially developed for our redesign
of the A6 TCR [14], we applied structure-based design to the
DMF5 TCR, generating variants and characterizing mutants with
affinity enhancements of up to 400-fold toward ELA/HLA-A2.
Highlighting the ability of structure-based design to directly target
regions of interest within protein interfaces, and in contrast with
results seen with in vitro selection, the strongest affinity enhancement
was achieved with only two previously identified amino acid
substitutions [25] that directly interact with the peptide. Impor-
tantly, the highest affinity variant showed no detectable recognition
of unrelated peptides presented by HLA-A2. We determined the
crystallographic structure of this variant bound to ELA/HLA-A2,
permitting a detailed analysis of the accuracy of the various
structural modeling protocols, and together with the affinity
measurements, a quantitative assessment of scoring functions and
terms. Further, by purposely disrupting interactions with the ELA
peptide, we were able to shift TCR specificity away from the ELA
peptide toward the AAG peptide, albeit with more modest efficacy.
Altogether, these results highlight the promise of structure-based
design for TCR engineering, and provide a rich dataset for further
improvements in design strategies, including the broadening of
efforts to other TCR-pMHC systems. Lastly, given the ongoing use
of the DMF5 TCR in efforts to develop immunological therapies for
melanoma (e.g., [26]), the high affinity DMF5 variants identified
here may have future clinical applicability.
Results
Design and Affinities of DMF5 Point Mutants
We used the ZAFFI and Rosetta software tools [14,27] to
predict the affinity changes of DMF5 mutants for ELA/HLA-A2
or AAG/HLA-A2, simulating all point mutations for each DMF5
residue within 5.5 Å of the pMHC ligand in the tertiary structures.
In total, we examined 589 substitutions of 31 DMF5 residues
within each complex, which were then ranked based on predicted
TCR-pMHC affinity. Twelve computationally designed mutations
were chosen for experimental testing. To help maintain peptide
specificity, with the exception of two aR27 mutants, we only chose
mutants that were predicted to contact the peptides. The aR27
mutants were selected to compare with our previously designed
substitutions at the corresponding position in the A6 TCR [14],
which shares the germline a chain gene (TRAV 12-2) and some
MHC contacts with DMF5. We performed mutagenesis using
soluble DMF5 gene constructs, expressed and purified the mutant
proteins, and measured their binding affinities toward ELA/HLA-
A2 and AAG/HLA-A2 via surface plasmon resonance (Figure 1).
The mutations and their measured affinities for ELA/HLA-A2
and AAG/HLA-A2 are given in Table 1, organized by the
method through which they were selected: Affinity, Specificity, or
Proline, as discussed in detail below. In addition, Table 1 includes
four mutations, listed under ‘‘Test’’, that we selected for
measurement based on manual inspection of the TCR-pMHC
structures.
Mutations in the Affinity category were chosen on the basis of
predicted enhancement in affinity towards both ELA/HLA-A2
and AAG/HLA-A2. Three of the six mutations in this category
had significantly improved affinities: aD26W, aD26Y, and
bL98W. The two aD26 mutants had the highest measured
binding affinities among all tested mutants (up to 40-fold
improvement for aD26W towards AAG/HLA-A2), while the
bL98W mutant had a 3-fold affinity improvement for both ELA/
HLA-A2 and AAG/HLA-A2.
Mutations in the Specificity category were chosen on the basis
of predicted differential affinity towards ELA/HLA-A2 and AAG/
HLA-A2. These were predicted to contact a portion of the
interface that varies between the two peptides, where the alanine
at the N-terminus of the nonamer is replaced by a larger glutamate
residue in the decamer (Figure S1). Several mutations at TCR
position aG28 were chosen that would potentially destabilize the
interaction with ELA/HLA-A2 via steric hindrance while favoring
AAG/HLA-A2. Of the specificity-altering substitutions, all shifted
specificity toward the AAG nonamer as predicted, albeit the shifts
were relatively modest (up to a 5-fold shift; Table 1 and Figure 2).
Based on work with the A6 TCR [28], as well as the observation
of proline CDR mutants in high affinity TCR selection
experiments [9,11], we tested three proline mutations that were
Author Summary
T cell receptors (TCRs) play a major role in immunity,
recognizing peptide antigens presented by major histo-
compatibility complex proteins. Due to their capacity to
target intracellularly produced proteins and initiate cell
killing, there is significant interest developing TCR-based
therapeutic strategies, particularly towards cancer. A
concern with TCRs is their weak-to-moderate affinities,
which limits therapeutic potential. While in vitro evolution
has been used to enhance TCR affinity, with sometimes
spectacular results, these techniques can reduce peptide
specificity and offer little control over affinity enhance-
ments. Here we explored the use of structure-based
computational design to enhance TCR affinity, which in
principle can permit control over both specificity and
affinity gains. We examined a clinically relevant TCR
recently used in melanoma immunotherapy, identifying
and characterizing mutations which enhanced affinity with
no detectable impacts on binding specificity. We solved a
crystal structure of our highest affinity designed TCR in
complex with antigen, which indicated high accuracy of
the structural modeling during the design process, and we
critically evaluated several design protocols and functions
to further improve design success. These results provide
valuable insights into the use of computational design for
TCRs. Lastly, the enhanced affinity variants identified may
be of potential clinical benefit.
Computational Design of a Therapeutic TCR
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Figure 1. Representative binding affinity measurements. (a) Steady-state binding equilibrium data for ELA/HLA-A2 binding wild type DMF5
and the bL98W and aG28P mutants. Solid lines represent a fit to a 1:1 equilibrium binding model. (b) Kinetic titration data for ELA/HLA-A2 binding of
the high affinity YW (aD26Y/bL98W) mutant of DMF5. Data are in black in the bottom panel; the red line is a fit to a 1:1 kinetic titration model with
drift. Residuals (difference between data and fitted curve) are shown in the smaller top panel.
doi:10.1371/journal.pcbi.1003478.g001
Table 1. DMF5 mutants organized by design strategy and measured affinities toward ELA/HLA-A2 and AAG/HLA-A2.
ELA AAG
Mutant KD, mM DDG, kcal/mol DDG Error Fold Change
1 KD, mM DDG, kcal/mol DDG Error Fold Change
1 Spec Change2
wild-type 9.5 - - - 43 - - - -
Affinity
aD26W 0.68 21.6 0.1 14 1.1 22.2 0.1 42 2.9
aD26Y 0.46 21.8 0.1 21 4.5 21.4 0.1 10 0.5
aR27W 26 0.6 0.1 0.4 62 0.2 0.1 0.7 1.9
bL98W 2.9 20.7 0.1 3.3 11 20.8 0.1 3.9 1.1
bF100W 46 0.9 0.1 0.2 83 0.4 0.1 0.5 2.5
bT102F 8.9 20.04 0.1 1.1 27 20.3 0.2 1.6 1.5
Specificity
aG28I 41 0.9 0.1 0.2 36 20.1 0.1 1.2 5.2
aG28L 99 1.4 0.1 0.1 130 0.7 0.1 0.3 3.4
aG28Y 120 1.5 0.1 0.1 110 0.5 0.1 0.4 5.2
Proline
aR27P 12 0.2 0.1 0.8 46 0.02 0.1 1.0 1.2
aG28P 60 1.1 0.2 0.2 340 1.2 0.2 0.1 0.8
bA55P 8.5 20.1 0.1 1.1 61 0.2 0.1 0.7 0.6
Test
aG28N 40 0.9 0.1 0.2 86 0.4 0.2 0.5 2.1
aY50A NB - - - NB - - - -
aG94T NB - - - NB - - - -
bF100Y 100 1.4 0.1 0.1 160 0.8 0.1 0.3 2.8
Combinations
aD26W/bL98W 0.033 23.3 0.1 290 0.60 22.6 0.1 72 0.2
aD26Y/bL98W 0.024 23.5 0.1 400 1.7 21.9 0.1 30 0.1
Bold denotes measured affinity improvements, or specificity changes, greater than 3-fold.
1Improvement in binding association constant relative to wild-type (KD_mut/KD_wt).
2Specificity change toward AAG versus ELA peptide: Fold_Change AAG/Fold_Change_ELA.
doi:10.1371/journal.pcbi.1003478.t001
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predicted to stabilize CDR loops in the bound conformation while
not negatively impacting contacts with the pMHC (Proline
category in Table 1). None of these proline substitutions showed
a significant improvement in affinity, indicating that while
potentially reducing the entropic cost for binding, the magnitudes
of any such improvements were not substantial enough to yield a
net increase in binding free energy, possibly because these loops
appear relatively rigid in the unbound DMF5 TCR [29].
Moreover, given the .1 kcal/mol loss in binding free energy
with both ELA/HLA-A2 and AAG/HLA-A2, the aG28P
substitution may have directly or indirectly impacted pMHC
contacts, consistent with its relatively buried position in the pMHC
interface.
Combining the affinity-enhancing aD26Y and bL98W muta-
tions (this double mutant is referred to as YW) yielded a substantial
improvement towards ELA/HLA-A2. This high affinity double
mutant was previously described in a brief report, with a
preliminary affinity measurement yielding an approximate 200-
fold enhancement [25]. Here, however, we measured a 400-fold
improvement (from 9.5 mM to 24 nM). The difference is
attributable to our use of a kinetic titration binding assay in this
case (Figure 1b), which is more accurate at quantifying binding in
the nanomolar range or higher, as it permits analyses of high
affinity binders without requiring surface regeneration [30]. The
on and off rates of the YW mutant towards ELA/HLA-A2
determined from the kinetic titration were 1.76106 M21 s21 and
0.05 s21, respectively. The dissociation rate of wild type DMF5
from ELA/HLA-A2 was too fast to accurately measure [29],
indicating that the combined mutations result in a slower TCR off
rate, as seen with the majority of affinity-enhanced TCRs [31].
The combined YW mutations were somewhat nonadditive
(23.5 kcal/mol enhancement versus 22.5 kcal/mol assuming
additivity), suggesting a modest degree of communication between
the CDR1a and CDR3b loops; the same degree of cooperativity
was also observed for the aD26W/bL98W (WW) mutant binding
ELA/HLA-A2 (Table 1). Nonadditivity within TCR binding
interfaces has been observed previously [32,33], and could be
attributable to structural or dynamic effects of mutations on
neighboring loops. The YW variant also showed a smaller but still
considerable 30-fold enhancement towards AAG/HLA-A2. The
reduced affinity enhancement is likely attributable to the lack of
the N-terminal glutamate in the AAG peptide as discussed below.
Given its dramatic affinity improvement toward both ELA/
HLA-A2 and AAG/HLA-A2, we next asked whether the high
affinity YW variant could recognize targets other than the MART-
1 nonamer and decamer. No binding was detectable towards
HLA-A2 presenting the Tax or gp100 peptides, even at
concentrations more than 25-fold higher than those used to
characterize binding to wild type DMF5 (Figure S2). The Tax and
gp100 peptides have markedly different sequences from ELA or
AAG (Tax: LLFGYPVYV; gp100: IMDQVPFSV), yet the
conformations of HLA-A2 are identical in the four peptide/
HLA-A2 crystal structures [24,34,35]. The lack of detectable
binding of the high affinity DMF5 YW variant towards the other
peptides thus suggests that we may have improved its specificity
towards the MART-1 peptides, and at the minimum demonstrates
that our design has avoided peptide-independent targeting of
HLA-A2.
Comparison with Predicted Affinities
To quantify the performance of the design methods that we
used to generate candidate mutations, ZAFFI and Rosetta, we
compared predicted versus measured affinities towards ELA/
HLA-A2 and AAG/HLA-A2 for each of the point mutations that
were experimentally characterized (excluding the aY50A and
aG94T mutants, for which binding was too weak to measure).
Mutants were scored with or without structural minimization
(referred to as Min and NoMin respectively), as shown in Figure 3
(with scores in Table 2). For both the Rosetta and ZAFFI scoring
functions, the NoMin simulations yielded higher agreement with
experimental data (Figure 3a–b), with the Rosetta scoring function
achieving an impressive 0.72 correlation with measured DDGs
(excluding four outlier points correctly predicted to have poor
affinities). Except for the proline mutant aG28P, the Rosetta
NoMin protocol made no other false positive predictions, and its
top four predictions (aD26Y and aD26W for the two pMHCs) had
the highest measured affinities among all predicted point
mutations (bL98W was also correctly ranked highly, particularly
for AAG). This predictive success is notable as the majority (8 out
of 14) of these mutants involved glycine and proline, which are
often overlooked during in silico studies due to difficulties
predicting backbone-related effects [27].
The ZAFFI NoMin protocol gave a correlation of 0.59 with
measured data (again excluding several true negative outlier points
due to predicted steric hindrance). Though it previously outper-
formed Rosetta in scoring A6 TCR mutants [14], and correctly
gave favorable scores for the DMF5 aD26 mutants, ZAFFI made
several false positive DMF5 predictions for both AAG/HLA-A2
and ELA/HLA-A2, possibly due to its parameterization on a more
limited dataset than Rosetta and the distinct biophysical properties
of the A6 and DMF5 interfaces. This led us to evaluate and
reparameterize the terms in the ZAFFI function using a larger set
of energy terms and mutants, as described further below.
Both minimization-based protocols (ZAFFI Min and Rosetta
Min; Figure 3c–d), while displaying positive correlations with the
experimental results, were lower in their predictive success than
the NoMin protocols. However, ZAFFI Min scored the aD26
mutants favorably, and correctly identified bL98W (for AAG) as
within the score cutoff for predicted binding improvement (#2
0.6; for ELA, bL98W was near this cutoff). Overall though, false
positive predictions for ZAFFI and Rosetta led to relatively weak
correlations, suggesting that minimization may have led to
Figure 2. DDG (in kcal/mol) for DMF5 point mutants for
nonameric (AAG) versus decameric (ELA) peptide bound to
HLA-A2. Solid line denotes equal DDG values, while dashed lines
denote a 4-fold affinity shift (0.82 kcal/mol) toward AAG (bottom
dashed line) or ELA (top dashed line). AAG and ELA DDG error bars are
shown for each mutant, while solid points are the aG28 substitutions
selected to shift preference toward the nonameric variant.
doi:10.1371/journal.pcbi.1003478.g002
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incorrect structures in some cases. We additionally tested other
minimization protocols as well as more extensive side chain
packing (Table S1), each of which gave lower correlations with
measured energies than the relatively restrictive NoMin protocol.
Crystal Structure of Mutant DMF5 YW in Complex with
ELA/HLA-A2
To examine the structural basis of the 400-fold binding affinity
improvement and compare with the models generated during the
design process, we crystallized and determined the structure of the
DMF5 YW mutant bound to ELA/HLA-A2 at 2.56 Å resolution
(Figure 4, with crystallographic data in Table S2). Clear electron
density was observed for the TCR-pMHC interface, and the
positions of the mutated amino acids were unambiguous as
indicated by an unbiased, iterative-build OMIT map [36] (Figure
S3). As with other structurally characterized TCRs engineered for
high pMHC affinity [12,13,37–39], the docking orientation was
conserved when compared to the wild-type complex, with a TCR-
pMHC crossing angle of 32u, versus 33u for the wild-type.
Essentially no perturbations of the interface CDR loops or peptide
were observed (0.34 Å backbone atom RMSD for TCR and
pMHC residues within 10 Å of the binding interface), indicating
that our relatively conservative design strategy of selecting point
substitutions against a fixed pMHC structure did not substantially
alter the interface or proximal side chains (Figure 4b–e). This tight
structural conservation of the binding loops and target pMHC
residues is in contrast to some high affinity TCRs generated by in
vitro selection where moderate (1G4 designs c5c1, c48c50, c58c61,
c58c62) [12,37] or pronounced (2C designs m6, m13, m67, and
Mel5 design a24b17) [13,38,39] perturbations of CDR loops were
exhibited, along with adjacent CDR loop remodeling [39] and
addition of a synergistic ion adduct in the interface [12]. In the
recently described structure of the c134 TCR [39] which is an in
vitro selected variant of the A6 TCR with nearly 1000-fold
improved affinity for Tax/HLA-A2, the mutant CDR3b loop
retained largely the same backbone structure as the wild-type loop,
yet it led to a shifted footprint of the a chain over the pMHC.
As anticipated from our modeling, both the tyrosine and
tryptophan mutant side chains directly contact the MART-1
peptide in the aD26Y/bL98W structure, and make more
extensive peptide contacts than their wild-type counterparts
(Table S3). These mutations led to a 5% increase in buried
solvent accessible surface area for the pMHC, from 1059 Å2 to
1113 Å2. Unexpectedly, as explicit water molecules were not used
in our structural modeling or scoring, a water-mediated hydrogen
bond to the peptide was introduced between the mutant residue
aY26 and the side chain of the N-terminal glutamate of the
Figure 3. Predicted versus measured DDGs for measured DMF5 point mutants binding to ELA/HLA-A2 (solid circles) and AAG/HLA-
A2 (empty triangles), using the Rosetta (a, c) and ZAFFI (b, d) functions. Mutations were modeled in Rosetta without minimization (a, b) or
with minimization of interface backbone and side chains (c, d). For (a) and (b), four outlier points with poor measured ELA/HLA-A2 binding and highly
unfavorable scores are not shown. For each plot, best fit lines and correlations (all calculated without the four outlier points for consistency) are
given.
doi:10.1371/journal.pcbi.1003478.g003
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peptide, in addition to a direct hydrogen bond between side chains
(Figure 4c). This polar network may explain the superior affinity of
aY26 versus aW26 for ELA/HLA-A2, despite the fact that they
were predicted to be similar (ZAFFI) or aW26 was preferred
(Rosetta; Table 2). In contrast, aD26W binds more strongly than
aD26Y to AAG/HLA-A2, which lacks the N-terminal peptide
glutamate and hydrogen bonding capability at that side chain. In
light of the water-mediated contacts observed in the mutant crystal
structure, we re-ran simulations using explicit water molecules
from the wild-type and mutant structures, but no improvement in
correlation was observed (Table S1).
Evaluation of Modeled Mutant Residues
The crystal structure of the YW variant bound to ELA/HLA-
A2 allowed us to evaluate the performance of several structural
Table 2. Scores from ZAFFI (ZF) and Rosetta (Ros), predicted peptide contacts, and measured energies (in kcal/mol) for DMF5
point mutants binding to ELA/HLA-A2 and AAG/HLA-A2.
ELA AAG
Mutant ZF Ros ZFMin RosMin Pep Conts1 DDG ZF Ros ZFMin RosMin Pep Conts1 DDG
aD26W 21.23 23.50 22.14 21.60 E1 21.56 21.17 23.30 21.84 20.50 22.21
aD26Y 21.28 21.58 21.82 21.00 E1 21.8 21.32 22.11 21.72 20.90 A1 21.36
aR27P 20.80 0.38 20.69 0.50 0.16 20.84 0.43 20.61 0.70 0.02
aR27W 20.18 0.83 21.06 0.20 0.6 20.04 0.37 21.55 0.00 0.2
aG28I 15.83 8.01 21.06 20.30 E1 0.87 22.18 20.67 21.59 20.70 A1 20.12
aG28L 38.09 29.33 21.53 20.80 E1 1.39 3.66 2.97 21.68 21.20 A1,A2 0.65
aG28N 9.50 5.00 0.34 0.10 E1 0.85 0.93 20.03 20.18 20.30 A1,A2 0.39
aG28P 5.30 1.29 20.59 0.80 E1 1.09 21.22 20.84 21.17 0.00 A1 1.2
aG28Y 9.21 4.38 20.92 20.60 E1 1.52 0.23 3.55 21.79 0.20 A1 0.53
aY50A 1.70 1.50 1.63 1.50 I5 .2.0 1.02 0.75 0.95 0.80 .2.0
aG94T 1.49 1.94 0.57 1.50 .2.0 6.89 4.83 1.36 3.40 .2.0
bA55P 20.29 20.20 20.23 20.20 20.07 20.29 20.29 20.25 0.50 0.19
bL98W 1.10 0.02 20.70 20.30 L8 20.71 20.25 20.83 21.02 20.40 L7,T8 20.8
bF100W 3.06 6.30 20.44 20.80 A3,G42 0.93 1.33 4.96 21.01 0.30 I4,I6,T8 0.37
bF100Y 2.33 2.39 0.81 2.10 G4 1.4 2.80 2.92 1.61 2.40 I4 0.77
bT102F 20.06 20.46 21.42 21.40 I5 20.04 20.01 20.13 20.25 0.80 20.29
Scores were produced using fixed backbone and fixed neighboring side chains (ZF, Ros) or minimization of interface backbone and side chains (ZFMin, RosMin) of wild-
type and mutant structures. Bold denotes measured DDG better than 20.25 kcal/mol, or prediction score of #20.6 for ZF or Ros, which we found to correspond to 2
0.25 kcal/mol based on fitting to 26 measured point mutations of the A6 TCR.
1Peptide residues within 6.0 Å of the predicted mutant side chain (modeled without minimization).
2Additional peptide residue contacts were predicted in the structural model; the two closest are shown.
doi:10.1371/journal.pcbi.1003478.t002
Figure 4. Structure of the DMF5 YW double mutant in complex with ELA/HLA-A2. (a) Superposition of the YW/ELA/HLA-A2 and the DMF5/
ELA/HLA-A2 complexes. DMF5 a chain is yellow, b chain is tan, peptide is magenta (shown as sticks), MHC is green, and b2m is cyan; residues that
were mutated are shown as sticks. Close-ups of (b) wild-type aD26, (c) mutant aY26, (d) wild-type bL98, (e) mutant bW98 are shown. In (b–e), residues
proximal to the mutation sites are shown as sticks, and in (c) hydrogen bonds involving the aY26 side chain and a bound water molecule are shown
as dashed lines.
doi:10.1371/journal.pcbi.1003478.g004
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modeling protocols. After least squares fitting of the backbone of
the TCR and pMHC interface residues to the crystal structure, we
compared positions of the modeled side chains to those in the
crystal structure (Figure 5, with RMSDs in Table 3). In addition to
the NoMin and Min methods, we evaluated models generated
using two intermediate minimization methods: MinSC (minimiz-
ing interface side chains only) and MinBB (minimizing interface
backbone atoms). Finally, we re-modeled the engineered side
chains in the context of the mutant crystal structure (NoMinMut)
to determine whether accurately positioned backbone and
neighboring side chain atoms could improve modeling results.
For modeling the side chain of aY26, all protocols performed
well in predicting the general orientation of the Tyr side chain,
with NoMin outperforming the other protocols (RMSD = 1.06 Å).
Though generally accurate, all models exhibited a rotation in the
aromatic ring and a slight shift in the OH group with respect to the
crystal structure. As these errors were possibly due to the absence
of explicit waters in the modeling omitting the water mediated
hydrogen bonding observed in the YW/ELA/HLA-A2 crystal
structure, we re-ran the NoMinMut simulation with water
molecules from that structure, but found little improvement in
RMSD (0.98 Å, versus 1.13 Å without water molecules).
The predicted side chain conformations for the mutant bL98W
were more variable than aY26, including a flip of the aromatic
rings in the Min and MinBB models, leading to relatively high
RMSDs (.2 Å) relative to the experimentally determined
structure for this residue. The structure modeled without
minimization had a sub-optimal positioning of the Trp side chain
(tilted away from the pMHC) (Figure 5), which improved
substantially (from 1.52 Å to 0.89 Å RMSD) when modeled in
the context of the backbone and side chains from the mutant
crystal structure. This indicates that Rosetta’s packing protocol is
sensitive to small structural perturbations and accurate modeling
of backbone and neighboring side chains can lead to improved
predictions.
Evaluation of Scoring Terms and Functions for Affinity
Prediction
In light of the lower accuracy of the ZAFFI scoring function on
the measured DMF5 point mutants (Figure 3) than for the A6
TCR, we performed a systematic evaluation of scoring functions to
better predict DMF5 affinities while still maintaining accuracy
with the set of A6 mutants. We included several statistical
potentials in addition to the energetic and knowledge-based terms
from the original ZAFFI study [14]. Given that minimization
yielded false positive results for both ZAFFI and Rosetta functions
(Figure 3) and that unminimized structures more closely matched
the YW-ELA/HLA-A2 crystal structure, we used unminimized
models for this analysis. In addition to correlation with measured
DDGs, we evaluated scoring functions using receiver operating
characteristic area under the curve (AUC) in order to judge
discrimination of binding improvement without penalizing true
negative or true positive outliers.
We identified a scoring function (referred to as ZAFFI 1.1) with
a higher correlation (0.74) than ZAFFI (0.59) and Rosetta (0.72)
for the set of DMF5 point mutants (excluding the four aG28
outlier mutants), and high AUC values for both DMF5 and A6
mutants (Table 4 and Figure S4). Correlation P-values are
included in Table 4 for all functions, highlighting significant
predictive performance of ZAFFI 1.1 (p,0.001) for both sets of
data. ZAFFI 1.1 includes six terms: van der Waals attractive and
repulsive components, desolvation, intra-residue clash, hydrogen
bonding and Coulombic electrostatics. While its correlation with
A6 TCR data (0.65) was not as high as the original ZAFFI
function (0.77), both the correlation and AUC are considerably
higher than Rosetta on that set of data. Although a few outlier
points persisted, including aG28P in the AAG/HLA-A2 interface,
the overall success of this function demonstrates that a relatively
simple scoring function and packing scheme can be used to model
a large proportion of energetic changes in three designed TCR-
pMHC interfaces. To examine the performance of this function in
the context of other protein-protein interactions, we applied it to
two large sets of interface point mutants (285 mutants each) of two
proteins designed de novo to target influenza hemagglutinin
(Table S4), recently used in a collaborative effort to evaluate
protein design algorithms as part of the protein docking
experiment CAPRI [40]. We found that ZAFFI 1.1 (with NoMin
packing) performed similarly to the other tested functions for
scoring the HB36 mutants (r = 0.36; p = 2.1610210), while for
HB80 mutants it outperformed all other functions (r = 0.5; p,
2.2610216), with a Kendall tau rank correlation (0.38) higher than
we achieved in the CAPRI experiment using a ZAFFI-related
function (0.31), where our Kendall correlation surpassed all other
groups [40].
Figure 5. Predicted structures of mutant residues (a) aD26Y
and (b) bL98W compared with the crystal structure. Colors for a
chain, b chain, peptide, MHC, and mutant side chains from the crystal
structure are as in Figure 4. Mutant side chains are shown as sticks, with
models in yellow (no minimization), cyan (with minimization), and
green (no minimization, in the context of the mutant crystal structure).
For simplicity, only the pMHC from the crystal structure is shown.
doi:10.1371/journal.pcbi.1003478.g005
Table 3. Root mean square distances (in Å) between
predicted mutant residues and those from the crystal
structure.
Protocol1 aD26Y bL98W
NoMin 1.06 1.52
MinSC 1.07 1.21
MinBB 1.6 2.26
Min 1.28 2.23
NoMinMut 1.13 (0.98) 0.89
1Modeling protocol used in Rosetta; NoMin denotes packing only the mutant
side chain without minimization while MinSC, MinBB, and Min denote
minimization of interface side chains, backbone atoms, or both, respectively.
NoMinMut utilized the NoMin protocol, starting with coordinates from the
mutant YW-ELA/HLA-A2 crystal structure (with mutant side chains removed
prior to modeling). For aD26Y, the value in parentheses is the RMSD with water
molecules from the YW-ELA/HLA-A2 structure included in the simulation.
doi:10.1371/journal.pcbi.1003478.t003
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Discussion
Structure-based design of TCRs provides a means to improve
upon low wild-type affinities for pMHC while maintaining,
improving, or altering specificities for desired targeting capabili-
ties. While some studies have determined the fine specificities of
designed TCRs using biophysical [39,41] and cell-based [23]
methods, here we demonstrated that point substitutions selected
using structure-based methods can be used to efficiently engineer
pMHC specificity and affinity. We then utilized structural
modeling and x-ray crystallography to gain atomic-level insights
into these substitutions. We achieved higher affinity improvements
than previously reported in structure-based TCR design, with just
two point substitutions resulting in an approximately 400-fold
affinity improvement, versus 150-fold for four combined point
mutants of the BC1 TCR selected using molecular mechanics
[16], and 100-fold for four combined point mutants of the A6
TCR selected using ZAFFI [14].
Despite the structural plasticity commonly observed in TCR-
pMHC interfaces [42–45], our computational modeling and
crystal structure indicate that carefully selected point substitutions
can improve pMHC affinity and modulate peptide specificity
without grossly perturbing the interface structure. We note though
that a broad extension this approach to other TCRs of interest will
likely entail further refinement of the energy function based on
measured data, in addition to improvements in high-resolution
modeling of TCR-pMHC complexes [46]. Large-scale datasets of
mutant binding affinities, including the CAPRI data we utilized to
assess our design functions [40], can provide possible training sets
for re-weighting terms and derivation of energy-based statistical
potentials that would add discriminating power and predictive
breadth to the ZAFFI function. Additionally, our analysis of the
YW-ELA/HLA-A2 structure indicates that there is room for
improving structural modeling of mutant residues, with modeling
of fine structural effects and bound water molecules representing
two avenues for further development.
The modulation of nonamer versus decamer specificity by many
point mutants of the DMF5 TCR highlights the sensitive nature of
TCR-antigen recognition, as well as the potential to fine-tune TCR
recognition properties via structure-based design. We achieved a
shift in specificity toward the nonameric MART-1 peptide via
mutation of aG28 residues that were predicted to clash with the
decameric E1 residue but would be accommodated in the cleft near
the nonameric A1, similar in concept to the ‘‘knob-in-to-hole’’
designs utilized to alter binding specificity in other protein-protein
interfaces [47]. The clash with the decamer was overestimated using
the NoMin modeling methods (which had the greatest overall
predictive success), thus leading to lower than anticipated specificity
shifts; better modeling of clashes through judicious use of
minimization (avoiding false positive predictions as we observed)
could potentially reduce such errors. In contrast, we found an
increase in specificity (.4-fold) toward the decameric peptide with
the DMF5 double mutants YW and WW, resulting from the
cooperativity of these mutants in the presence of the decamer. This
peptide-dependent cooperative effect is a previously undescribed
mechanism for shifting TCR specificity. As the structure of the
YW/ELA/HLA-A2 complex did not suggest any major alterations
in the binding interface compared to the wild-type complex, this
effect may be dynamic in nature. As recently reported, the Mel5
TCR mutant a24b17, which targets ELA/HLA-A2 with a 30,000-
fold affinity improvement over wild-type, was found to retain
peptide specificity, albeit towards alanine substituted ELA variants
rather than between the ELA and AAG decameric/nonameric
peptides [13]. In this case specificity was mediated through subtle
solvent interactions. By modeling solvent and dynamic effects, as
well as exploring explicit specificity design methods, such as multi-
state design [48], greater control of TCR specificity could be
achieved via rational engineering.
Three of the a chain mutants we tested were previously
examined in the A6 TCR (aD26W, aG28I, and aG28L) [14],
whose CDR1a and CDR2a loops are identical to DMF5 due to
the common use of the TRAV12-2 gene. aD26W improved
pMHC affinity significantly for both TCRs, though to varying
extents. On the other hand, the aG28 mutants improved the
affinity of A6 modestly (,2-fold) but resulted in no change or
weakened affinity with DMF5. This behavior likely follows from
the positions of the mutations, as the aG28 mutants are predicted
to make extensive contacts with the varying N-terminus of the
peptide, while aD26W would primarily target the same HLA-A2
site to improve affinities for all three pMHCs. However, both
aD26 mutants of DMF5 still exhibited a measurable peptide
dependence with DDG, compared with, for instance, bL98W
which had identical effects in the context of both MART-1
peptides. Data from more mutants and positions, as well as other
TCR-pMHC systems, such as the Mel5 TCR which shares the
TRAV12-2 gene with DMF5 and A6 and also targets ELA/HLA-
A2 with a similar docking mode [49], would help to further
delineate the extent of any conserved effects of affinity-enhancing
or destabilizing mutants. Indeed, the structure of the high affinity
a24b17 Mel5 TCR mutant in complex with ELA/HLA-A2 [13]
features a large hydrophobic substitution at position aD26 (Phe),
which closely matches the aD26Y conformation and the pMHC
binding site in the YW/ELA/HLA-A2 structure (Figure S5),
although as Mel5 a24b17 contained 18 additional substitutions,
the energetic effect of aD26F alone is unclear. A more detailed
study of the impact of affinity-enhancing mutations in germline
CDRs would help to further probe TCR germline binding
permissiveness suggested by a recent double mutant cycle
deconstruction of the interface with the A6 TCR [50].
In conclusion, we have shown that rational, computational-
based design offers the potential to simultaneously alter the
efficacy and antigen targeting of a therapeutic TCR, potentially
enabling the development of improved TCRs for adoptive cell
therapy [51] or biotherapeutics [52] customized to bind antigens
presented by tumors or virally infected cells from individual
patients. Given the ongoing use of the DMF5 TCR in clinical trials
for cancer immunotherapy, the higher-affinity YW variant of
DMF5 generated here may also be of potential clinical benefit.
Table 4. Correlation and ROC AUC values of tested energy
functions and structural modeling methods for DMF5 and A6
TCR point mutants.
Function Packing DMF5 Corr1
DMF5
AUC2 A6 Corr3
A6
AUC3
Rosetta NoMin 0.72 (,1024) 0.95 0.42 (,1021) 0.79
ZAFFI NoMin 0.59 (,1022) 0.86 0.77 (,1025) 0.92
Rosetta Min 0.54 (,1022) 0.82 0.52 (,1022) 0.75
ZAFFI Min 0.54 (,1022) 0.77 0.56 (,1022) 0.79
ZAFFI 1.1 NoMin 0.73 (,1024) 0.93 0.63 (,1023) 0.92
124 points with DDG values, excluding four (true negative) outliers.
2All 32 tested ELA and AAG mutants.
326 previously measured A6 TCR point mutants.
Values in parentheses are correlation p-values.
Values in bold indicate correlation .0.6, p-value,1023, or AUC.0.9.
doi:10.1371/journal.pcbi.1003478.t004
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Methods
Simulation and Scoring of DMF5 Point Mutations
As with our previous study designing the A6 TCR [14], we used
the ‘‘interface’’ mode of Rosetta 2.0.2 [27] to model point
mutations of the DMF5 TCR. Command line options were
specified to include extra chi1, chi2, and chi3 rotamers
(‘‘-extrachi_cutoff 1 -ex1 -ex2 -ex3’’). Only the mutant side chain
was repacked (the default behavior of this mode) while the protein
backbone from the wild-type structure was retained. Rosetta
predicted mutant structures as well as DDGs, and the structures
were then re-scored by our energetic scoring function ZAFFI to
generate its own set of predicted DDG scores. The ZAFFI filter,
parameterized using the A6 TCR data and designed to remove
false positive predictions that destabilized native electrostatic
contacts, was not used in this study, given that our focus was
evaluation and development of binding energy prediction func-
tions, and the new system and protocols being explored would
require tuning of the parameters of this filter. However, the filter
function was used to corroborate avoidance of mutations in some
cases (such as hydrophobic mutants of aQ30) where key hydrogen
bonds would likely be disrupted.
To generate predictions of point mutants using side chain and/
or backbone minimization we used Rosetta 2.3, a more recent
version of this program that includes minimization functionality in
its interface mutagenesis mode. Minimization was specified using
the command line flags (‘‘-min_interface -int_bb -int_chi’’) to
perform minimization of interface backbone and side chain atoms
in the wild type and mutant structures (‘‘Min’’ protocol), while just
‘‘-int_chi’’ or ‘‘-int_bb’’ was used to perform only side chain or
backbone minimization (‘‘MinChi’’, ‘‘MinBB’’). Point mutant
simulations with explicit water molecules taken from the input
structure were also performed using Rosetta 2.3, using the
command line flag: ‘‘-read_hetero_h2o’’.
Selection of Proline Mutants
We analyzed residue backbone conformations in the bound and
unbound DMF5 TCR structures using a Ramachandran plot
analysis server [53] (http://zlab.bu.edu/rama/). DMF5 CDR
positions with favorable backbone conformations for proline (as
well as favorable pre-proline conformations for the preceding
residue), in addition to either improved or maintained pMHC
affinity predicted for the proline mutant by at least one prediction
method, were selected for experimental mutation to proline.
Protein Expression and Purification
Expression and refolding of soluble constructs of DMF5 TCRs
and HLA-A2 were performed as previously described [29,54]. In
brief, the TCR a- and b-chains, the HLA-A2 heavy chain, and b2-
microglobulin (b2m) were generated in Escherichia coli as inclusion
bodies, which were isolated and denatured in 8 M urea. TCR a-
and b-chains were diluted in TCR refolding buffer (50 mM Tris
(pH 8), 2 mM EDTA, 2.5 M urea, 9.6 mM cysteamine, 5.5 mM
cystamine, 0.2 mM PMSF) at a 1:1 ratio. HLA-A2 and b2m were
diluted in MHC refolding buffer (100 mM Tris (pH 8), 2 mM
EDTA, 400 mM L-arginine, 6.3 mM cysteamine, 3.7 mM
cystamine, 0.2 mM PMSF) at a 1:1 ratio in the presence of excess
peptide. TCR and pMHC complexes were incubated for 24 h at
4uC. Afterward, complexes were desalted by dialysis at 4uC and
room temperature respectively, then purified by anion exchange
followed by size-exclusion chromatography. Refolded protein
absorptions at 280 nm were measured spectroscopically and
concentrations determined with appropriate extinction coeffi-
cients. Mutations in the DMF5 a- and b-chains were generated by
PCR mutagenesis and confirmed by sequencing. Peptides and
plasmids were commercially synthesized and purified (Genscript).
Surface Plasmon Resonance
Surface plasmon resonance experiments were performed with a
Biacore 3000 instrument using CM5 sensor chips. In all
experiments, TCR was immobilized to the sensor chip via
standard amine coupling and pMHC complex was injected as
analyte. All samples were thoroughly dialyzed in HBS-EP buffer
(20 mM HEPES (pH 7.4), 150 mM NaCl, 0.005% Nonidet P-20),
then degassed for at least 15 minutes prior to use. Steady-state
experiments were performed with TCRs coupled onto the sensor
chip at 1000–1500 response units. Injections of pMHC spanned a
concentration range of 0.5–150 mM at flow rates of 5 ml/min at
25uC. Multiple data sets were globally fit using a 1:1 Langmuir
binding model utilizing BIAevaluation 4.1. Kinetic titration
experiments were performed with TCRs coupled at approximately
500 response units. A series of five ELA titrations, spanning 10–
160 nM and 20–320 nM at 2-fold increase per titration, were
flowed over YW and WW respectively. Flow rates of 30 ml/min
were used at 25uC. Data were fit with a 1:1 association model with
drift using BIAevaluation [30].
Crystallization, Diffraction Data Collection, Structural
Refinement and Analysis
Crystals of the DMF5 YW-ELA/HLA-A2 complexes were
grown from 12% PEG 3350, 0.25 M MgCl2 buffered with 0.1 M
HEPES (pH 8.0) at 25uC. Crystallization was performed using
sitting drop/vapor diffusion. For cryoprotection, crystals were
transferred into 20% glycerol/80% mother liquor for 30 s and
immediately frozen in liquid nitrogen. Diffraction data were
collected at the 22ID (SER-CAT) beamlines at the Advanced
Photon Source, Argonne National Laboratories. Data reduction
was performed with HKL2000. The ternary complexes were
solved by molecular replacement using PHENIX and Protein
Data Bank (PDB) entry 3QDG as the reference model [29]. Rigid
body refinement, followed by translation/libration/screw (TLS)
refinement and multiple steps of restrained refinement were
performed. TLS groups were automatically chosen by phenix.re-
fine. Once defined, TLS parameters were included in all
subsequent steps of the refinement. Anisotropic and bulk solvent
corrections were taken into account throughout refinement. After
TLS refinement, it was possible to unambiguously trace the
position of peptides and TCR CDR loops in all structures against
sA-weighted 2Fo-Fc maps. Evaluation of models and fitting to
maps were performed using COOT [55]. The template structure
check in WHATIF [56] and MolProbity [57] was used to evaluate
the structures during and after refinement. Atomic positioning was
verified with an iterative-build OMIT map calculated in PHENIX
[36]. Structures were visualized using PyMOL [58]. Analysis of
hydrogen bonds was performed with HBPlus [59], using
hydrogen-acceptor maximum distance of 2.7 Å and a donor-
acceptor maximum distance of 3.6 Å. Solvent accessible surface
areas were measured in Discovery Studio (Accelrys Inc.) using a
probe radius of 1.4 Å. The structure has been deposited with the
Protein Data Bank (PDB ID 4L3E).
Analysis and Retraining Scoring of Affinities
ROC AUC analysis was performed using the CROC package
[60]. Multi-linear regression to determine weighting of terms was
performed as described previously, using 760 measured point
mutants from four enzyme-inhibitor complexes [14]. However, we
used van der Waals attractive and repulsive terms from Rosetta
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[27] rather than the corresponding terms from ZRANK [61], as
the former led to some improvement in performance across the
tested systems. As with the original ZAFFI training, we removed
mutants with high clash during training (van der Waals repulsive
score .580, corresponding to 48 mutants removed out of 760).
We included a number of statistical potential terms for evaluation
that were recently tested for binding affinity prediction [62],
though none led to substantial improvements in predictive
performance in this context. The terms and weights for the
retrained energy function (ZAFFI 1.1) are:
van der Waals attractive: 0.57
van der Waals repulsive: 0.0045
solvation: 0.58
hydrogen bonding: 1.2
intra-residue repulsion: 0.026
electrostatics: 0.03
Solvation, hydrogen bonding, and intra-residue repulsion terms
were obtained from Rosetta (along with the van der Waals terms
as noted above), while the electrostatics term is the long-range
Coulombic electrostatics energy from ZRANK [61].
Correlations
All correlations (with the exception of the Kendall tau rank
correlations reported in Table S4) are Pearson correlations. P-
values for correlations were calculated using the program R (www.
r-project.org).
Supporting Information
Figure S1 Structural variability of nonameric (AAG; cyan) and
decameric (ELA; magenta) MART-1 peptides bound to wild-type
DMF5 (from wild-type complex structures, PDB IDs 3QDJ and
3QDG). MHC and TCR colors are as in Figure 4; DMF5 residue
aG28 is shown as spheres for reference.
(PDF)
Figure S2 The high affinity DMF5 variants show no recognition
of the Tax11–19 or gp100209(2M)-217 peptide/HLA-A2 complexes.
a) Injections over a wild-type DMF5 surface. The main response
shows injections of MART-126(27L)-35/HLA-A2, with the binding
response indicated. The inset shows injections of gp100/HLA-A2
and Tax/HLA-A2 over the same surface, with no response at
concentrations as high as 400 mM. b) Injections over a high
affinity YW DMF5 surface. Injected pMHC is as in panel a. c)
Injections over a high affinity WW DMF5 surface. Injected
pMHC is as in panel a.
(PDF)
Figure S3 Electron density for bW98 (gold) and aY26 (purple) in
the YW-ELA/HLA-A2 crystal structure contoured at 1s
calculated from an unbiased, iterative-build OMIT map. The
density shows the clear, unambiguous positioning of the two
mutated residues.
(PDF)
Figure S4 Predictions from ZAFFI 1.1 compared with measured
DDGs for DMF5 point mutants binding to ELA/HLA-A2 (solid
circles) and AAG/HLA-A2 (empty triangles). Best fit line and
correlation are given; the four true negative outlier points omitted
from Figure 3 are omitted here as well.
(PDF)
Figure S5 Comparison of mutant TCR aD26Y residue in the
YW-ELA/HLA-A2 complex with the corresponding mutant
position (aD27F) in the a24b17-ELA/HLA-A2 complex. Com-
plexes were superposed by fitting pMHC backbone atoms. The
mutant aD27F is shown in orange sticks, ELA peptide from
a24b17-ELA/HLA-A2 in pink sticks, and all other colors are as in
Figure 4.
(PDF)
Table S1 DMF5 mutant predictive performance for additional
tested packing protocols.
(PDF)
Table S2 X-ray data collection and refinement statistics for the
crystal structure of the DMF5 aD26Y/bL98W - ELA/HLA-A2
complex.
(PDF)
Table S3 Contacts between mutant DMF5 residues and ELA/
HLA-A2.
(PDF)
Table S4 Correlations with measured values and corresponding
p-values for HB36 and HB80 mutants.
(PDF)
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